INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.
(Updates with the latest stock movement and additional details in the first paragraph and headline.)
2026-11-02. The following slide deck was published by Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares jumped 229% to $1.98 after the drug developer said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, its first commercial product. The treatment aims to reduce surgeries in adults with recurrent respiratory...
Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP. VOCERYQ is the co
Inovio surges after FDA approves Voceryq for rare HPV-linked recurrent respiratory papillomatosis, marking a first for a DNA-based immunotherapy. Read more here.
This is the newest page. Registered accounts read further back.